Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors

<div>High positive ratios of FGFR1-4 were predicted in certain types of cancer. (a) The cutoff value was set to 4,220 to reach FGFR1 or 3 positive ratio of 42%, which was curated from preliminary results from an ongoing clinical trial (<a href="https://clinicaltrials.gov/ct2/show/NCT01976741">NCT01976741</a>) in advanced bladder cancer patients prescreened for FGFR1 or 3 mRNA expression levels by RNA-ISH. Here, we assume that FGFR1- or 3-positive ratio by RNA-ISH is positively correlated with RSEM value by RNA-Seq in TCGA. (b) Predicted positive ratios of FGFR1-4 in pancancer.</div>

BioMed Research International

fig4

Figure 4

Figure 4: Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors 